Drugs / DIROCAFTOR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03251092 | Jul 2017 → Dec 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03140527 Comparator | Apr 2017 → Feb 2020 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03500263 Comparator | Jan 2018 → Mar 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIROCAFTOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594297 ↗ |
| Known as | PTI-808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03500263 ↗ |
| Modality | Small molecule | — CHEMBL4594297 ↗ |